Controversy Brews Over Cold and Flu Syrups for Kids: Experts Call for Safer Alternatives
Maxtra, T-Minic, Ascoril AF, and other popular cold and flu syrups for children are facing a potential ban as India’s Drug Technical Advisory Board (DTAB) reviews their safety for children under four. The panel has recommended halting the sale of formulations containing "Chlorpheniramine Maleate IP + Phenylephrine Hydrochloride" due to concerns over their effects on young patients.
This combination is commonly found in many leading brands, including Haleon's T-Minic, Zuventus' Maxtra, and Glenmark's Ascoril Flu Drops. While these medications help alleviate symptoms like runny noses and sneezing, experts warn that they may pose risks to young children.
The DTAB's discussions, which involved pediatric specialists, revealed significant concerns about the safety of these syrups for children under four. The committee emphasized the need for clear labeling to alert parents about the risks associated with these medications.
Doctors express a cautious approach to banning these medications outright. Many believe that restrictions should only be enforced if safer, evidence-based alternatives are available. "Banning is easy, but without other options, misuse may increase," said a pediatrician seeking anonymity.
Dr. Maninder Dhaliwal, a pediatric pulmonology expert, echoed these concerns, advocating for well-researched alternatives to be provided alongside any restrictions. He argues that while warnings on labels can protect against misuse, clarity is vital to maintain trust between parents and healthcare providers.
Globally, health authorities are also reconsidering the use of cough and cold medications for children, with studies showing little evidence of their effectiveness for treating acute coughs and colds. Despite concerns about potential side effects—ranging from dizziness to serious complications—many cases of toxicity result from therapeutic errors rather than the medications themselves.
As discussions continue, the focus remains on ensuring that children receive safe and effective treatment for their ailments, prompting an urgent call for innovative alternatives in pediatric care.
